Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Emerging roles of tRNA-derived small RNAs in cancer biology
Experimental & Molecular Medicine Open Access 10 July 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. tRNA therapeutics burst onto startup scene. Nat Biotechnol 40, 283–286 (2022). https://doi.org/10.1038/s41587-022-01252-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01252-y
This article is cited by
-
tRNA therapeutics for genetic diseases
Nature Reviews Drug Discovery (2024)
-
Emerging roles of tRNA-derived small RNAs in cancer biology
Experimental & Molecular Medicine (2023)